ABT vs AFL Stock Comparison

Scores Breakdown

Metric	ABT	AFL
📈 Growth	18/30	6/30
💰 Profitability	17/20	18/20
🏦 Financial Health	18/20	15/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	7/10
Overall Score	71/100	54/100

Side-by-Side Summaries

ABT Analysis	AFL Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Eight quarters show a revenue path from $5.403B (2024 Q3) to $4.117B (2026 Q2). A trough occurred in 2025 Q1 with $4.16B rev and $29M net income. Revenues then recovered to the high 4.7–4.9B range in 2025 H2, before easing again to $4.12B in 2026 Q2. Net income moved from $1.902B (2024 Q3) to $0.825B (2026 Q2), with a dip to $29M in 2025 Q1. Overall, the trend is negative on revenue and earnings, but several quarters display strong operating performance (notably 2024 Q3 and late-2025/2026). 💰 Margins & Cash Flow Operating margins were robust on several quarters, averaging in the mid-60s percent, peaking around 75% in 2024 Q3 and hovering near 70% in late 2025–2026; a trough around 40–41% occurred in 2025 Q2. Cash flow from operations remained positive across periods (e.g., $315M in 2024 Q4, $1.27B in 2025 Q3, $112M in 2026 Q2), while investing/financing swings produced occasional negative free cash flow (notably 2025 Q1 and 2026 Q1). 🛡️ Balance Sheet & Liquidity Current assets consistently exceed current liabilities (e.g., 2026 Q2: Current Assets $115.96B vs Current Liabilities $85.65B). Total assets run in the $116–$125B range with equity around $28–$30B, indicating a solid reserve position given insurer-liability balances. Leverage remains typical for an insurance franchise, with ample liquidity cushions. ⚠️ Key Drivers & Risks Drivers: Stable insurance premium streams and investment income support, with favorable rate environments aiding capital generation. Risks: Earnings volatility from reserve dynamics and regulatory shifts; sensitivity to interest-rate changes and macro cycle could compress margins during downturns.

ABT Analysis

AFL Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Eight quarters show a revenue path from $5.403B (2024 Q3) to $4.117B (2026 Q2). A trough occurred in 2025 Q1 with $4.16B rev and $29M net income. Revenues then recovered to the high 4.7–4.9B range in 2025 H2, before easing again to $4.12B in 2026 Q2. Net income moved from $1.902B (2024 Q3) to $0.825B (2026 Q2), with a dip to $29M in 2025 Q1. Overall, the trend is negative on revenue and earnings, but several quarters display strong operating performance (notably 2024 Q3 and late-2025/2026).

💰 Margins & Cash Flow

Operating margins were robust on several quarters, averaging in the mid-60s percent, peaking around 75% in 2024 Q3 and hovering near 70% in late 2025–2026; a trough around 40–41% occurred in 2025 Q2. Cash flow from operations remained positive across periods (e.g., $315M in 2024 Q4, $1.27B in 2025 Q3, $112M in 2026 Q2), while investing/financing swings produced occasional negative free cash flow (notably 2025 Q1 and 2026 Q1).

🛡️ Balance Sheet & Liquidity

Current assets consistently exceed current liabilities (e.g., 2026 Q2: Current Assets $115.96B vs Current Liabilities $85.65B). Total assets run in the $116–$125B range with equity around $28–$30B, indicating a solid reserve position given insurer-liability balances. Leverage remains typical for an insurance franchise, with ample liquidity cushions.

⚠️ Key Drivers & Risks

Drivers: Stable insurance premium streams and investment income support, with favorable rate environments aiding capital generation.
Risks: Earnings volatility from reserve dynamics and regulatory shifts; sensitivity to interest-rate changes and macro cycle could compress margins during downturns.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"